EZH2抑制剂他泽司他治疗复发或难治性BAP1失活恶性胸膜间皮瘤患者:一项多中心、开放标签、2期研究
这项多中心开放标签单臂2期研究在法国、英国和美国的16家医院纳入74例复发或难治性恶性胸膜间皮瘤患者,其中73例(99%)为BAP1失活肿瘤,评估口服他泽司他的抗肿瘤活性与安全性。第2部分第12周疾病控制率为54%(95%CI 42-67;61例中33例),无确认的完全缓解,2例确认的部分缓解持续时间分别为18周和42周。最常见的3-4级治疗中出现的不良事件为高血糖(5例[7%])、低钠血症(5例[7%])和贫血(4例[5%]),25例(34%)报告严重不良事件,5例(7%)在研究期间死亡,无治疗相关死亡。
要点
- BAP1失活恶性胸膜间皮瘤患者第12周疾病控制率为54%(95%CI 42-67;61例中33例)。
- 无确认的完全缓解,2例确认的部分缓解持续时间分别为18周和42周。
- 最常见3-4级治疗中出现不良事件为高血糖(5例[7%])、低钠血症(5例[7%])和贫血(4例[5%])。
核心结论
- 在BAP1失活之外进一步细化他泽司他活性的生物标志物,可能有助于识别最可能从该治疗获得持久获益或肿瘤缩小的肿瘤亚组。
研究设计与样本
- 开放标签、单臂2期研究,在法国、英国和美国的16家医院开展。
- 2016年7月29日至2017年6月2日共纳入74例患者(第1部分13例,第2部分61例),均接受他泽司他治疗,其中73例(99%)为BAP1失活肿瘤。
- 入组条件为年龄18岁及以上、任何组织学类型的恶性胸膜间皮瘤、至少一种含培美曲塞方案治疗后复发或难治、ECOG体能状态0或1、预期寿命大于3个月。
- 第1部分患者第1天口服他泽司他800 mg一次,第2天起每日两次;第2部分患者自第1周期第1天起口服他泽司他800 mg每日两次,采用两阶段Green-Dahlberg设计。
- 他泽司他以21天为一周期给药,约17个周期;第1部分主要终点为第15天他泽司他及其代谢物的药代动力学,第2部分主要终点为第12周疾病控制率。
主要发现
- 第1部分第1周期第15天重复给药达稳态后,平均Cmax为829 ng/mL(变异系数56.3%),中位Tmax为2小时(范围1-4),平均AUC0-t为3310 h·ng/mL(变异系数50.4%),平均AUC0-∞为3180 h·ng/mL(46.6%),几何平均t1/2为3.1小时(13.9%)。
- 中位随访35.9周(IQR 20.6-85.9)后,第2部分BAP1失活恶性胸膜间皮瘤患者第12周疾病控制率为54%(95%CI 42-67;61例中33例)。
- 无患者达到确认的完全缓解;2例患者达到确认的部分缓解,1例部分缓解持续18周且仍在进行,另1例持续42周。
- 最常见的3-4级治疗中出现的不良事件为高血糖(5例[7%])、低钠血症(5例[7%])和贫血(4例[5%]);74例中25例(34%)报告严重不良事件。
- 74例中5例(7%)在研究期间死亡,无治疗相关死亡。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Treatment options for malignant pleural mesothelioma are scarce. Tazemetostat, a selective oral enhancer of zeste homolog 2 (EZH2) inhibitor, has shown antitumour activity in several haematological cancers and solid tumours. We aimed to evaluate the anti-tumour activity and safety of tazemetostat in patients with measurable relapsed or refractory malignant pleural mesothelioma. METHODS: We conducted an open-label, single-arm phase 2 study at 16 hospitals in France, the UK, and the USA. Eligible patients were aged 18 years or older with malignant pleural mesothelioma of any histology that was relapsed or refractory after treatment with at least one pemetrexed-containing regimen, an Eastern Cooperative Oncology Group performance status of 0 or 1, and a life expectancy of greater than 3 months. In part 1 of the study, participants received oral tazemetostat 800 mg once on day 1 and then twice daily from day 2 onwards. In part 2, participants received oral tazemetostat 800 mg twice daily starting on day 1 of cycle 1, using a two-stage Green-Dahlberg design. Tazemetostat was administered in 21-day cycles for approximately 17 cycles. The primary endpoint of part 1 was the pharmacokinetics of tazemetostat and its metabolite at day 15 after administration of 800 mg tazemetostat, as measured by maximum serum concentration (Cmax), time to Cmax (Tmax), area under the concentration-time curve (AUC) to day 15 (AUC0-t), area under the curve from time 0 extrapolated to infinity (AUC0-∞), and the half-life (t1/2) of tazemetostat, assessed in all patients enrolled in part 1. The primary endpoint of part 2 was the disease control rate (the proportion of patients with a complete response, partial response, or stable disease) at week 12 in patients with malignant pleural mesothelioma per protocol with BAP1 inactivation determined by immunohistochemistry. The safety population included all the patients who had at least one post-dose safety assessment. This trial is now complete and is registered with ClinicalTrials.gov, NCT02860286. FINDINGS: Between July 29, 2016, and June 2, 2017, 74 patients were enrolled (13 in part 1 and 61 in part 2) and received tazemetostat, 73 (99%) of whom had BAP1-inactivated tumours. In part 1, following repeat dosing of tazemetostat at steady state, on day 15 of cycle 1, the mean Cmax was 829 ng/mL (coefficient of variation 56·3%), median Tmax was 2 h (range 1-4), mean AUC0-twas 3310 h·ng/mL (coefficient of variation 50·4%), mean AUC0-∞ was 3180 h·ng/mL (46·6%), and the geometric mean t1/2 was 3·1 h (13·9%). After a median follow-up of 35·9 weeks (IQR 20·6-85·9), the disease control rate in part 2 in patients with BAP1-inactivated malignant pleural mesothelioma was 54% (95% CI 42-67; 33 of 61 patients) at week 12. No patients had a confirmed complete response. Two patients had a confirmed partial response: one had an ongoing partial response with a duration of 18 weeks and the other had a duration of 42 weeks. The most common grade 3-4 treatment-emergent adverse events were hyperglycaemia (five [7%] patients), hyponatraemia (five [7%]), and anaemia (four [5%]); serious adverse events were reported in 25 (34%) of 74 patients. Five (7%) of 74 patients died while on study; no treatment-related deaths occurred. INTERPRETATION: Further refinement of biomarkers for tazemetostat activity in malignant pleural mesothelioma beyond BAP1 inactivation could help identify a subset of tumours that are most likely to derive prolonged benefit or shrinkage from this therapy. FUNDING: Epizyme.
引用
- Zauderer MG, Szlosarek PW, Le Moulec S, et al. EZH2 inhibitor tazemetostat in patients with relapsed or refractory, BAP1-inactivated malignant pleural mesothelioma: a multicentre, open-label, phase 2 study. Lancet Oncol. 2022. PMID: 35588752. doi:10.1016/S1470-2045(22)00277-7
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。